The IMB was a national participant in a European review which concluded today at 4.30pm that the risks of rosiglitazone containing medicines outweigh their benefits. In the interests of patient safety, the recommendation is that the marketing authorisation for rosiglitazone-containing medicines should be suspended across the European Union. This recommendation has now been forwarded to the European Commission for the adoption of a legally binding decision.

Further information, including advice to prescribers, is contained in the attached fax which was issued this afternoon by the IMB to healthcare professionals. In addition, the IMB has issued the attached press release.

Further information, including a Questions and Answers Document, is also available from the EMA  www.ema.europa.eu  website.